Zimmer Biomet (NYSE:ZBH) Updates FY 2025 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 8.150-8.350 for the period, compared to the consensus estimate of 8.550. The company issued revenue guidance of $7.8 billion-$7.9 billion, compared to the consensus revenue estimate of $8.0 billion.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday. Oppenheimer reduced their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Royal Bank of Canada decreased their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, JMP Securities restated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $124.70.

Zimmer Biomet Trading Down 1.6 %

NYSE ZBH opened at $101.01 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. The stock’s 50-day moving average is $107.34 and its 200-day moving average is $108.10. Zimmer Biomet has a one year low of $99.93 and a one year high of $133.90. The firm has a market cap of $20.11 billion, a P/E ratio of 22.70, a P/E/G ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 EPS. Sell-side analysts anticipate that Zimmer Biomet will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.